{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:50:06Z","timestamp":1782211806741,"version":"3.54.5"},"reference-count":22,"publisher":"Termedia Sp. z.o.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Pathol"],"abstract":"<jats:p>Thymic epithelial tumours are rare malignancies of\u00a0the\u00a0anterior superior mediastinum. Several studies have analysed the\u00a0presence of\u00a0c-KIT mutations in thymic carcinoma. Immunohistochemical c-KIT expression and mutations in exons 8, 9, 11, 13, 14, 17, and 18 of the KIT gene and in the promoter region of the TERT gene (chr5, 1,295,228C&gt;T\/A and 1,295,250C&gt;T) were analysed by PCR based direct sequencing using representative formalin-fixed paraffin-embedded tumour samples of 18 thymic carcinomas. Of 18 patients, 4 test samples were excluded from the\u00a0study due to inadequate DNA quality. Of 14 patients with thymic carcinomas, KIT and TERT mutation was not detected in any samples. C-KIT expression was associated with nearly a\u00a0worse overall survival (median time 24.160-49.840, log-rank, p\u00a0=\u00a00.05). We showed that squamous cell carcinomas led to worse survival than other subtypes. As expected, TNM stage II was significantly correlated with better OS (p = 0.015). Thymic carcinoma is characterised by a\u00a0KIT-positive and CD5-positive staining pattern. We report a\u00a0worse overall survival for patients with c-kit expressing tumours. These data suggest a\u00a0negative prognostic role for c-kit expression especially within the\u00a0first 5 years.<\/jats:p>","DOI":"10.5114\/pjp.2020.97019","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T17:10:58Z","timestamp":1595783458000},"page":"120-126","source":"Crossref","is-referenced-by-count":5,"title":["C-KIT mutation in thymic carcinomas"],"prefix":"10.5114","volume":"71","author":[{"given":"Neslihan Kaya","family":"Terzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebnem","family":"Batur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulcin","family":"Yegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Yol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evsen Apaydin","family":"Arikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysim Buge","family":"Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"ref-1696244","doi-asserted-by":"crossref","unstructured":"Rossana B, Mariagrazia LD, Silvia P, et al. Thymic Malignancies in the\u00a0Targeted Therapies Era. J Carcinog Mutagen 2014; S8: 008.","DOI":"10.4172\/2157-2518.S8-008"},{"key":"ref-1696245","unstructured":"Pagano M, Sierra NMA, Panebianco M, et al. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. Anticancer Res 2014; 34: 5105-5110."},{"key":"ref-1696246","unstructured":"Travis WD, Brambilla E, Burke AP, et al. (eds.) WHO classification of\u00a0tumours of\u00a0the\u00a0lung, pleura, thymus and heart. IARC Press, Lyon 2015."},{"key":"ref-1696247","doi-asserted-by":"crossref","unstructured":"Kondo K, Monden Y. Therapy for thymic epithelial tumours: a\u00a0clinical study of\u00a01,320 patients from Japan. Ann Thorac Surg 2003; 76: 878-884.","DOI":"10.1016\/S0003-4975(03)00555-1"},{"key":"ref-1696248","doi-asserted-by":"crossref","unstructured":"Girard N, Mornex F, Van Houtte P, et al. Thymoma: a\u00a0focus on current therapeutic management. J Thorac Oncol 2009; 4: 119-126.","DOI":"10.1097\/JTO.0b013e31818e105c"},{"key":"ref-1696249","doi-asserted-by":"crossref","unstructured":"Rossi V, Donini M, Sergio P, et al. When a\u00a0thymic carcinoma \u201cbecomes\u201d a\u00a0GIST. Lung Cancer 2013; 80: 106-108.","DOI":"10.1016\/j.lungcan.2013.01.003"},{"key":"ref-1696250","doi-asserted-by":"crossref","unstructured":"Yilmaz I, Gamsizkan M, Ozturk Sari S, et al. Molecular alterations in malignant blue nevi and related blue lesions. Virchows Arch 2015; 467: 723-732.","DOI":"10.1007\/s00428-015-1851-3"},{"key":"ref-1696251","doi-asserted-by":"crossref","unstructured":"Onder S, Ozturk Sari S, Yegen G, et al. Classic Architecture with Multicentricity and Local Recurrence, and Absence of\u00a0TERT Promoter Mutations are Correlates of\u00a0BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. Endocr Pathol 2016; 27: 153-161.","DOI":"10.1007\/s12022-016-9420-0"},{"key":"ref-1696252","doi-asserted-by":"crossref","unstructured":"Buti S, Donini M, Sergio P, et al. Impressive response with imatinib in a\u00a0heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol 2011; 29: e803-e805.","DOI":"10.1200\/JCO.2011.36.6427"},{"key":"ref-1696253","doi-asserted-by":"crossref","unstructured":"Petrini I, Zucali PA, Lee HS, et al. Expression and Mutational Status of\u00a0c-kit in Thymic Epithelial Tumors. J Thorac Oncol 2010; 5: 1447-1453.","DOI":"10.1097\/JTO.0b013e3181e96e30"},{"key":"ref-1696254","doi-asserted-by":"crossref","unstructured":"Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004; 130: 222-224.","DOI":"10.1007\/s00432-004-0545-z"},{"key":"ref-1696255","unstructured":"Natali PG, Nicotra MR, Sures I, et al. Expression of\u00a0c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52: 6139-6143."},{"key":"ref-1696256","doi-asserted-by":"crossref","unstructured":"Pan C, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004; 202: 375-381.","DOI":"10.1002\/path.1514"},{"key":"ref-1696257","doi-asserted-by":"crossref","unstructured":"Tsuchida M, Umezu H, Hashimoto T, et al. Absence of\u00a0gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 2008; 62: 321-325.","DOI":"10.1016\/j.lungcan.2008.03.035"},{"key":"ref-1696258","unstructured":"Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis gastrointestinal stromal\/smooth muscle tumors. Lab Invest 1998; 78: 1633-1636."},{"key":"ref-1696259","doi-asserted-by":"crossref","unstructured":"Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of\u00a0mutated KIT and the\u00a0response to Imatinib. New Engl J Med 2004; 350: 2625-2626.","DOI":"10.1056\/NEJM200406173502523"},{"key":"ref-1696260","doi-asserted-by":"crossref","unstructured":"Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of\u00a0EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008; 62: 316-320.","DOI":"10.1016\/j.lungcan.2008.03.013"},{"key":"ref-1696261","doi-asserted-by":"crossref","unstructured":"Bisagni G, Rossi G, Cavazza A, et al. Long lasting response to the\u00a0multikinase inhibitor bay 43-9006 (Sorafenib) in a\u00a0heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009; 4: 773-775.","DOI":"10.1097\/JTO.0b013e3181a52e25"},{"key":"ref-1696262","doi-asserted-by":"crossref","unstructured":"Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009; 15: 6790-6799.","DOI":"10.1158\/1078-0432.CCR-09-0644"},{"key":"ref-1696263","doi-asserted-by":"crossref","unstructured":"Hamada S, Masago K, Mio T, Hirota S, Mishima M. Good clinical response to imatinibmesylate in atypical thymic carcinoid with KIT overexpression. J Clin Oncol 2011; 29: e9-10.","DOI":"10.1200\/JCO.2010.30.2455"},{"key":"ref-1696264","doi-asserted-by":"crossref","unstructured":"Thomas de Montpr\u00e9ville V, Ghigna MR, et al. Thymic carcinomas: clinicopathologic study of\u00a037 cases from a\u00a0single institution. Virchows Arch 2013; 462: 307-313.","DOI":"10.1007\/s00428-013-1371-y"},{"key":"ref-1696265","doi-asserted-by":"crossref","unstructured":"Kondo K. Tumor-node metastasis staging system for thymic epithelial tumors. J Thorac Oncol 2010; 5: S352-S356.","DOI":"10.1097\/JTO.0b013e3181f20f3b"}],"container-title":["Polish Journal of Pathology"],"original-title":[],"link":[{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-120127-136756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-120127-136756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:31:19Z","timestamp":1782210679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polishjournalofpathology.com\/C-KIT-mutation-in-thymic-carcinomas,120127,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["120127"],"URL":"https:\/\/doi.org\/10.5114\/pjp.2020.97019","relation":{},"ISSN":["1233-9687","2084-9869"],"issn-type":[{"value":"1233-9687","type":"print"},{"value":"2084-9869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]}}}